Biochip as a potential platform of serological interferon α2b antibody assay

Journal of Biotechnology

Volumn 106, Issue 1, 2003, Pages 87-100

  Du, Weidong ^a   Xu, Zhenshan ^b   Ma, Xueling ^a   Song, Lihua ^b   Schneider, E Marion ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Anhui Biology Institute   (China)

Author keywords

Biochip; N Hydroxysuccinimide; Recombinant human interferon 2b; Serum immunoassay

Indexed keywords

ANTIBODIES; GROWTH KINETICS; HORMONES; IMMUNOLOGY; TUMORS; VIRUSES;

BIOCHIP METHODOLOGY;

INTERFERONS;

ALPHA2B INTERFERON; GROWTH HORMONE; GROWTH HORMONE ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERFERON ANTIBODY; LEPTIN; LEPTIN ANTIBODY; MONOCLONAL ANTIBODY; N HYDROXYSUCCINIMIDE; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; LEUKEMIA; METHODOLOGY; MOLECULAR SIZE; PRIORITY JOURNAL; PROTEIN DETERMINATION; SEROLOGY; SERUM; SOLID TUMOR;

EID: 0242494108     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2003.08.001     Document Type: Article

References (45)

1. Antonelli G., Currenti M., Turriziani O., Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 163:1991;882-885.
2. Arai K., Shindo M., Okuno T. Anti-interferon antibody in chronic hepatitis C on interferon. Nippon Rinsho. 52:1994;1929-1934.
3. Bain C.D., Evall J., Whitesides G.M. Formation of monolayers by coadsorption of thiols on gold: variation in the head group, tail group, and solvent. J. Am. Chem. Soc. 111:1989;7155-7164.
4. Bell J.B., Barfoot R., Iveson T., Powles R.L., Millar B.C. Neutralizing antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b. Br. J. Cancer. 70:1994;646-651.
5. Bendtzen K., Hansen M.B., Ross C., Svenson M. Detection of autoantibodies to cytokines. Mol. Biotechnol. 14:2000;251-261.
6. Brintrup J., Du W., Ortigao F.R., Krause M., Debatin K.M., Kohne E., Hug H. Easy and rapid detection of point mutations in the human beta-hemoglobin gene with DNA-biochips. Biotechnology. 2:2003;121-130.
7. Cabiedes J., Cabral A.R., Lopez-Mendoza A.T., Cordero-Esperon H.A., Huerta M.T., Alarcon-Segovia D. Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects. J. Autoimmune. 18:2002;181-190.
8. Cieplik, M., Galanina, O., Klingel, S., Nivantév, N., Videnov, G., Pfeiffer, M., Bovin, N., Mecklenburg, M., Ortigao, F., 2001. A Versatile BioChip Format Applied to Blood Serology. Feature Article September/October, pp. 12-14.
9. Crance J.M., Leveque F., Jouan A., Trepo C. Antiviral effect of recombinant interferon-alpha on hepatitis A virus replication in human liver cells. C.R. Acad. Sci. III. 317:1994;94-97.
10. Di Pucchio T., Lapenta C., Santini S.M., Logozzi M., Parlato S., Belardelli F. CD2+/CD14+ monocytes rapidly differentiate into CD83+ dendritic cells. Eur. J. Immunol. 33:2003;358-367.
11. Du W., Cieplik M., Durstewitz G., Sarkar C.M., Kruschina M., Fries R., Ortigao F.R. Minisequencing on functionalised self-assembled monolayer as a simple approach for single nucleotide polymorphism analysis of cattle. Z. Naturforschung, Section C. 58c:2003;413-420.
12. Dutcher J.P., Logan T., Gordon M., Sosman J., Weiss G., Margolin K., Plasse T., Mier J., Lotze M., Clark J., Atkins M. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin. Cancer Res. 6:2000;3442-3450.
13. Espejo A., Cote J., Bednarek A., Richard S., Bedford M.T. A protein domain microarray identifies novel protein-protein interactions. Biochem. J. 367:2002;697-702.
14. Freund M., von Wussow P., Diedrich H., Eisert R., Link H., Wilke H., Buchholz F., LeBlanc S., Fonatsch C., Deicher H. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br. J. Haematol. 72:1989;350-356.
15. Hou C., Chuang W.L., Yu M.L., Dai C.Y., Chen S.C., Lin Z.Y., Hsieh M.Y., Wang L.Y., Tsai J.F., Chang W.Y. Incidence and associated factors of neutralizing anti-interferon antibodies among chronic hepatitis C patients treated with interferon in Taiwan. Scand. J. Gastroenterol. 35:2000;1288-1293.
16. Hunziker L., Recher M., Macpherson A.J., Ciurea A., Freigang S., Hengartner H., Zinkernagel R.M. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat. Immunol. 4:2003;343-349.
17. Ikeda Y., Miyake K., Toda G., Yamada H., Yamanaka M., Oka H. Detection of anti-interferon-alpha 2a antibodies in chronic liver disease. J. Gastroenterol. Hepatol. 4:1989;411-418.
18. Ikeda Y., Toda G., Hashimoto N., Umeda N., Miyake K., Yamanaka M., Kurokowa K. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis. Clin. Exp. Immunol. 85:1991;80-84.
19. Johnsson B., Loefaes S., Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal. Biochem. 198:1991;268-277.
20. Larocca A.P., Leung S.C., Marcus S.G., Colby C.B., Borden E.C. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J. Interferon Res. 9(Suppl. 1):1989;S51-S60.
21. Liberek A., Luczak G., Bako W., Korzon M., Rytlewska M., Sikorska-Wisniewska G., Szlagatys-Sidorkiewicz A. Prognostic factors in the treatment of chronic hepatitis B with interferon alpha in children. Med. Sci. Monit. 7(Suppl. 1):2001;127-137.
22. Llovet J.M., Sala M., Castells L., Suarez Y., Vilana R., Bianchi L., Ayuso C., Vargas V., Rodes J., Bruix J. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 31:2000;54-58.
23. Mangia A., Santoro R., Piattelli M., Leandro G., Minerva N., Annese M., Bacca D., Spirito F., Carretta V., Ventrella F., Cela M., Andriulli A. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J. Hepatol. 37:2002;109-116.
24. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., Willcox N. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 132:2003;128-136.
25. Mecklenburg, M., Danielsson, B., Winqvist, F., 1996. Broad Specific Arrays: A Qualitative Approach to Complex Sample Discrimination. Patent SE, PCT/EP, 97/03317.
26. Millot F., Brice P., Philippe N., Thyss A., Demeoq F., Wetterwald M., Boccara J.F., Vilque J.P., Guyotat D., Guilhot J., Guilhot F. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia. J. Pediatr. Hematol. Oncol. 24:2002;18-22.
27. Paquette R.L., Hsu N., Said J., Mohammed M., Rao N.P., Shih G., Schiller G., Sawyers C., Glaspy J.A. Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia. 16:2002;1484-1489.
28. Pavlickova P., Jensen N.M., Paul H., Schaeferling M., Giammasi C., Kruschina M., Du W., Theisen M., Ibba M., Ortigao F., Kambhampati D. Antibody detection of human serum using a versatile protein chip platform constructed by applying of nano-scale self-assembled architecture on gold. J. Proteome Res. 1:2002;227-231.
29. Pavlickova P., Knappik A., Kambhampati D., Ortigao F., Hug H. Microarray of recombinant antibodies using a streptavidin sensor surface self-assembled onto a gold layer. Biotechniques. 34:2003;124-130.
30. Persson H.H.J., Caseri W.R., Suter U.W. Versatile method for chemical reactions with self-assembled monolayers of alkanethiol on gold. Langmuir. 17:2001;3643-3650.
31. Peter J.C., Briand J.P., Hoebeke J. How biotinylation can interfere with recognition: a surface plasmon resonance study of peptide-antibody interactions. J. Immunol. Methods. 274:2003;149-158.
32. Porres J.C., Carreno V., Ruiz M., Marron J.A., Bartolome J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J. Hepatol. 8:1989;351-357.
33. Puoti M., Rossi S., Forleo M.A., Zaltron S., Spinetti A., Putzolu V., Rodella A., Carosi G. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J. Hepatol. 29:1998;45-52.
34. Roep B.O., Hiemstra H.S., Schloot N.C., De Vries R.R., Chaudhuri A., Behan P.O., Drijfhout J.W. Molecular mimicry in type 1 diabetes: immune crossreactivity between islet autoantigen and human cytomegalovirus but not Coxsackie virus. Ann. N.Y. Acad. Sci. 958:2002;163-165.
35. Russo D., Candoni A., Zuffa E., Minisini R., Silvestri F., Fanin R., Zaja F., Martinelli G., Tura S., Botta G., Baccarani M. Neutralizing antiinterferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha. Br. J. Haematol. 94:1996;300-305.
36. Saenko E., Kannicht C., Loster K., Sarafanov A., Khrenov A., Kouiavskaia D., Shima M., Ananyeva N., Schwinn H., Gruber G., Josic D. Development and applications of surface plasmon resonance-based von Willebrand factor collagen binding assay. Anal. Biochem. 302:2002;252-262.
37. Spiegel R.J., Jacobs S.L., Treuhaft M.W. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective. J. Interferon Res. 9(Suppl. 1):1989;S17-S24.
38. Steinmann G.G., God B., Rosenkaimer F., Adolf G., Bidlingmaier G., Fruhbeis B., Lamche H., Lindner J., Patzelt E., Schmahling C. Low incidence of antibody formation due to long-term interferon-alpha 2c treatment of cancer patients. Clin. Investig. 70:1992;136-141.
39. Stellato G., Nieminen P., Aho M., Lehtinen T., Lehtinen M., Paavonen J. Type 1 cytokine response and treatment outcome of genital HPV lesions. Genitourin. Med. 73:1997;387-390.
40. Stewart T. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. 14:2003;139-154.
41. Turner R.B., Felton A., Kosak K., Kelsey D.K., Meschievitz C.K. Prevention of experimental corona virus colds with intranasal alpha-2b interferon. J. Infect. Dis. 154:1986;443-447.
42. Vallbracht A., Treuner J., Flehmig B., Joester K.E., Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature. 289:1981;496-497.
43. Vo-Dinh T., Cullum B. Biosensors and biochips: advances in biological and medical diagnostics. Fr. J. Anal. Chem. 366:2000;540-551.
44. Wilson W.H., Kingma D.W., Raffeld M., Wittes R.E., Jaffe E.S. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood. 87:1996;4531-4537.
45. Yabrov A. It is hazardous to treat HIV patients with interferon-alpha? Med. Hypotheses. 54:2000;131-136.